EHA 2018 | Incorporating novel therapies into frontline ALL treatment
Oliver Ottmann
• 14 Jun 2018
Eliminating high toxicity, invasive treatments like chemotherapy and stem cell transplant is a goal of acute lymphoblastic leukemia (ALL) research. Here, Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK speaks from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, about small molecule novel therapies in the context of ALL. He discusses the great potential for combination therapies, using novel agents alongside immunotherapies like monoclonal antibodies and CAR T-cells, in order to reduce and eventually eradicate the need for chemotherapy and stem cell transplants in the future.
